StockData
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. (XENE) stock

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.78−0.48 (-1.22%)

Close on Nov 17, 2026Market cap $3.76BP/E –Yield –

Xenon Pharmaceuticals r&d expenses

Research and development expenses are spending on new products and technology.

Xenon Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $352.49M, up 39.5% year over year. For fiscal 2025 it was $300.94M, up 43.0% from the year before. Over ten years it grew 34.8% a year on average. The highest annual figure on record is $300.94M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$300.94M+43.0%
FY2024Dec 31, 2024$210.39M+25.6%
FY2023Dec 31, 2023$167.51M+58.4%
FY2022Dec 31, 2022$105.77M+40.2%
FY2021Dec 31, 2021$75.46M+49.4%
FY2020Dec 31, 2020$50.52M+30.1%
FY2019Dec 31, 2019$38.85M+64.4%
FY2018Dec 31, 2018$23.63M-7.6%
FY2017Dec 31, 2017$25.57M+29.0%
FY2016Dec 31, 2016$19.83M+30.9%
FY2015Dec 31, 2015$15.15M+28.8%
FY2014Dec 31, 2014$11.77M-4.3%
FY2013Dec 31, 2013$12.30M+17.7%
FY2012Dec 31, 2012$10.46M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$99.22M+32.3%
Q1 FY2026Mar 31, 2026$88.51M+44.6%
Q4 FY2025Dec 31, 2025$87.70M+47.5%
Q3 FY2025Sep 30, 2025$77.05M+35.3%
Q2 FY2025Jun 30, 2025$74.99M+50.9%
Q1 FY2025Mar 31, 2025$61.20M+38.3%
Q4 FY2024Dec 31, 2024$59.47M+44.8%
Q3 FY2024Sep 30, 2024$56.97M+32.9%
Q2 FY2024Jun 30, 2024$49.70M+12.9%
Q1 FY2024Mar 31, 2024$44.25M+12.0%
Q4 FY2023Dec 31, 2023$41.08M+17.9%
Q3 FY2023Sep 30, 2023$42.88M+45.7%
Q2 FY2023Jun 30, 2023$44.04M+98.9%
Q1 FY2023Mar 31, 2023$39.52M+104.1%
Q4 FY2022Dec 31, 2022$34.83M+59.1%
Q3 FY2022Sep 30, 2022$29.43M+55.8%
Q2 FY2022Jun 30, 2022$22.15M+20.5%
Q1 FY2022Mar 31, 2022$19.36M+18.7%
Q4 FY2021Dec 31, 2021$21.89M+46.2%
Q3 FY2021Sep 30, 2021$18.89M+44.8%
Q2 FY2021Jun 30, 2021$18.38M+71.4%
Q1 FY2021Mar 31, 2021$16.31M+38.3%
Q4 FY2020Dec 31, 2020$14.97M+27.4%
Q3 FY2020Sep 30, 2020$13.05M+33.8%
Q2 FY2020Jun 30, 2020$10.72M+30.7%
Q1 FY2020Mar 31, 2020$11.79M+29.0%
Q4 FY2019Dec 31, 2019$11.75M+83.6%
Q3 FY2019Sep 30, 2019$9.75M+56.1%
Q2 FY2019Jun 30, 2019$8.21M+51.5%
Q1 FY2019Mar 31, 2019$9.14M+64.1%
Q4 FY2018Dec 31, 2018$6.40M+0.1%
Q3 FY2018Sep 30, 2018$6.25M-12.8%
Q2 FY2018Jun 30, 2018$5.42M-11.3%
Q1 FY2018Mar 31, 2018$5.57M-5.7%
Q4 FY2017Dec 31, 2017$6.40M+45.5%
Q3 FY2017Sep 30, 2017$7.16M+20.1%
Q2 FY2017Jun 30, 2017$6.11M–
Q1 FY2017Mar 31, 2017$5.90M–
Q4 FY2016Dec 31, 2016$4.40M–
Q3 FY2016Sep 30, 2016$5.97M–

More Xenon Pharmaceuticals figures

See a number that looks wrong?